However, these drugs may be not recommended in diabetic patients affected by pancreatic cancer (Mohelnikova-Duchonova et al., 2013), triple-negative breast cancer (Hlaváč et al., 2013), and lung adenocarcinoma (Wang et al., 2020), where the low expression of ABCC8/Sur1 is associated with poor prognosis with drug–disease interaction. Here, ABCC8 is linked to triple-negative breast carcinoma.